1. Introduction {#sec1}
===============

The prevalence of type 2 diabetes is estimated to be 6% (42.08 mmol/mol) for the adult population of Austria \[[@B1]\], thus posing a relevant threat to population health. Guideline adherent, structured treatment and management of the disease as proposed by disease management programmes (DMPs) are seen as the best strategy in the prevention of diabetic complications, but evidence from RCTs and systematic reviews on DMPs reveal only modest effects on patient care \[[@B2], [@B3]\], especially regarding the frequency of clinically relevant endpoints \[[@B4]\]. The Austrian DMP "Therapie Aktiv," implemented by statutory health insurance in 2007, had no significant effects on metabolic control in a cluster-randomised trial \[[@B5]\] and an open follow-up study \[[@B6]\].

While DMPs have been shown to improve process quality of care \[[@B5]\], they insufficiently address lifestyle changes like physical activity. A logical next step in the improvement of DMPs is therefore the design and implementation of additional components addressing these deficits. Most promising components are interventions to increase physical activity, to decrease caloric intake, and to improve patient education. A Cochrane review on exercise in patients with type 2 diabetes showed that physical activity significantly reduced HbA~1c~ by 0.62% (−16.72 mmol/mol) \[[@B7]\]. Reduced caloric intake and increased physical activity led to weight loss and to a significant improvement of metabolic control and risk factor profile in the Look-AHEAD trial \[[@B8], [@B9]\]. Patient education has been shown to improve metabolic control in several systematic reviews \[[@B10]--[@B12]\]. On the other hand, in all the studies cited above, success and improvement have been moderate and were achieved by quite intensive interventions involving professional support which can hardly be implemented on a population-wide level due to economic and structural reasons.

An alternative might be to emphasize self-management and peer-to-peer motivation instead of professionally dominated educational interventions. Thus a combination of traditional disease management with ongoing peer support may be a promising approach in diabetes care that deserves further evaluation. The idea of peer support goes back as far as the late 1980s, when the impact of diabetes education and peer support were first evaluated \[[@B13]\]. A systematic review of controlled intervention studies on the effect of social and peer support in diabetes identified six randomised trials that all showed some beneficial effects \[[@B14]\] but further studies questioned these early positive results. Although some evidence for the effectiveness of ongoing peer support on metabolic control has been presented \[[@B15], [@B16]\], a systematic review found this evidence to be too limited to support firm recommendations and calls for further well-designed studies \[[@B17]\]. No such studies have been done on the implementation of long-term peer support programmes added to a traditional DMP. We therefore designed the peer support programme "Aktivtreff Diabetes" as an additional component of the Austrian DMP "Therapie Aktiv" for type 2 diabetes and evaluated the effectiveness of the programme in a cluster-randomised controlled trial.

2. Methods {#sec2}
==========

2.1. Design {#sec2.1}
-----------

We designed our evaluation study as a pragmatic cluster-randomised controlled trial set in general practices in the province of Salzburg in Austria.

2.2. Participants {#sec2.2}
-----------------

We invited all 77 surgeries actively administering the DMP "Therapie Aktiv" in Salzburg to recruit participants for the study. All 1327 patients enrolled in the DMP were eligible to participate. We encouraged general practitioners to continuously recruit patients within a recruitment period of eight months (September 2010--April 2011). In addition, Salzburg public health insurance sent an invitation letter to all patients enrolled in the DMP. All patients willing to participate were included in the study after obtaining written informed consent according to the declaration of Helsinki. Exclusion criteria were the following: type 1 diabetes, dementia or major psychiatric illness, advanced neoplastic disease, or other diseases with drastically reduced life expectancy by physician judgement.

2.3. Intervention {#sec2.3}
-----------------

The intervention was carried out over a period of two years from May 2011 to May 2013 and consisted of four elements which were implemented in addition to the ongoing DMP.

### 2.3.1. Recruitment of Peer Supporters {#sec2.3.1}

General practitioners suggested two peer supporters per intervention group who were made familiar with the details of the study and invited to the peer supporter training. Peer supporters are nonprofessionals who have type 2 diabetes. The peer supporters\' main tasks were the following: organization of group meetings and exercise units as well as log of attendance, facilitation of group discussions on diabetes related topics, support of physically weak group members, and motivation of unmotivated participants. Throughout all responsibilities, peer supporters were encouraged to rather give support than advice. They played a crucial role as contact persons for the participants and for the research team. Peer supporters were reimbursed with 10€ per group meeting.

### 2.3.2. Peer Supporter Training {#sec2.3.2}

During the first year of intervention peer supporters received six sessions of training (four hours each). We compiled a standardised curriculum for the training in order to assure reproducibility within the trial and for any application afterwards. Professionals trained peer supporters addressing the following topics: the concept of peer support, organisation of group meetings, physical activity, recommendations for the treatment and management of type 2 diabetes, motivation, medical aspects of diabetes, nutrition, experience, and feedback.

### 2.3.3. Physical Exercise Meetings {#sec2.3.3}

Peer groups consisting of 8--12 participants met once every week for at least one hour of physical outdoor activity such as (Nordic) walking combined with other exercises. The first meetings were facilitated by a physical education trainer to get the groups started and familiarise them with the intervention and exercises. Thereafter, groups met largely autonomously and trainers supported the groups only when needed. The peer groups were regularly provided with instruction sheets (nine in total) showing and explaining exercises for mobilisation, coordination, and strength training.

### 2.3.4. Peer Group Meetings (Table 1) {#sec2.3.4}

[](#tab1){ref-type="table"}Once a month groups held conversational and educational meetings focusing on personal, social, and emotional topics in the context of diabetes. The meetings were moderated alternately by peer supporters and health professionals and offered the opportunity to ask particular questions and expand and consolidate knowledge about diabetes. To assure standardisation and coverage of the most important topics, we developed a curriculum. It guided participants through subject areas that changed every other month and provided matched topics for every single session. Prior to each meeting, all participants received a newsletter addressing the corresponding topic including the latest scientific findings.

Patients in the control groups received standard care according to the DMP "Therapie Aktiv" which enforces care according to international guidelines regarding monitoring, diagnostics, and treatment of type 2 diabetes.

2.4. Outcomes {#sec2.4}
-------------

The primary outcome measure was the difference in change of HbA~1c~ (%, resp., mmol/mol, determined by HPLC using a Menarini HA-8180 HPLC Analyser) from baseline to 24 months between the intervention and control groups. Prespecified secondary outcome measures comprised quality of life EQ-5D-3L index and EQ-5D visual analogue scale (VAS) \[[@B18]\], improved control of cardiovascular risk factors (systolic and diastolic blood pressure measured in the general practices according to standard WHO criteria using locally available gauged blood pressure monitors, total cholesterol, HDL cholesterol, and triglycerides, determined at local laboratories with automated clinical chemistry analysers, and LDL cholesterol, determined using the Friedewald equation), lowering of global cardiovascular risk (UKPDS-Risk Engine 2.0) \[[@B19]\], change in body weight (body mass index (BMI)), and smoking cessation (self-reported).

All primary and secondary outcomes were measured between October 2010 and April 2011 for baseline and between October 2012 and April 2013 for follow-up.

Baseline and follow-up data were recorded pseudonymised by the general practitioners using the structured documentation sheet of the disease management programme "Therapie Aktiv" and case report forms which were then sent to the study centre. We checked all forms for completeness and plausibility. In case of missing or implausible data, we contacted the responsible general practitioner.

2.5. Sample Size {#sec2.5}
----------------

We calculated sample size for *α* = 0.05 and *β* = 0.20, proposing 0.5% (−18.03 mmol/mol) difference between intervention and control groups in change of HbA~1c~ from baseline to final examination at 24 months. Using an estimated standard deviation of 1.2% (−10.38 mmol/mol) for HbA~1c~ change, a sample size of 181 patients (91 per arm) was required. Assuming an intracluster correlation coefficient of 0.05 (derived from our previous study \[[@B5]\]) and an average cluster size of 12 patients per peer group, we estimated a design effect of *D* = 1 + (12 − 1) × 0.05 = 1.55. Thus, the sample size increased to 280 patients (140 per arm). Allowing for up to 20% loss to follow-up, the sample size was adjusted to 175 patients per arm or a total of 350 patients.

2.6. Randomisation {#sec2.6}
------------------

To assure concealment of allocation, all patients were cluster-randomised by electronic sequence generation using Research Randomizer \[[@B20]\] after completion of recruitment and allocation of patients to prospective peer groups as clusters. Clustering was performed by the study management grouping 8--12 patients living close to each other into a cluster to facilitate face-to-face meetings. If there were a sufficient number of patients in a region, we aimed to group younger patients (\<65 years) and older patients (≥65 years) in separate clusters. This resulted in three categories of clusters: category 1: mostly patients \<65 years; category 2: mostly patients ≥65 years; category 3: clusters with patients of all ages. Randomisation was stratified by cluster category. When participants signed up and were clustered, neither the study management nor physicians nor patients knew which group would participate in the peer support programme or serve as control, to assure concealment of allocation. Randomisation at the patient level would not have been feasible because the intervention addresses the group.

2.7. Blinding {#sec2.7}
-------------

Due to the nature of the intervention, blinding was not possible.

2.8. Statistical Analysis {#sec2.8}
-------------------------

All statistical analyses were performed with IBM SPSS Statistics 20.0. We evaluated our primary endpoint in an intention-to-treat analysis according to the CONSORT guidelines for the reporting of cluster-randomised controlled trials \[[@B21]\]. For missing data regarding HbA~1c~ we applied the method of last available data carried forward. For unadjusted, univariate analysis, we used an independent *t*-test (two-tailed) to detect significant differences between the intervention and the control group. Per-protocol analysis was performed for all secondary outcomes, using independent *t*-tests to detect differences between groups.

In addition to univariate analysis we used a mixed model approach to account for nesting of patients in peer groups and to adjust for covariates. We calculated intracluster correlation coefficients (ICC) and then adjusted for cluster effects, age, and baseline value.

2.9. Ethics Approval and Trial Registration {#sec2.9}
-------------------------------------------

The study protocol was presented to the ethics committee of the province of Salzburg and received unconditional ethics approval on February 24, 2010. The study was registered with current controlled trials on November 17, 2010 ([ISRCTN10291077](http://www.isrctn.com/ISRCTN10291077)).

3. Results {#sec3}
==========

3.1. Participants, Recruitment {#sec3.1}
------------------------------

Forty-nine (63.6%) of the eligible general practices (*n* = 77) recruited patients for the study. A total of *n* = 420 (29.6%) of all eligible patients (*n* = 1327) initially signed up. Twenty-seven patients did not meet inclusion criteria. Fifty-six patients withdrew consent after randomisation (54 interventions, 2 controls), and 9 patients died (5 interventions, 4 controls), leaving 328 patients for intention-to-treat analysis (intervention group: *n* = 143; control group: *n* = 185). [Figure 1](#fig1){ref-type="fig"} shows the CONSORT flow diagram of the study. For 23 patients (intervention group: *n* = 4; control group: *n* = 19) final HbA~1c~ had to be imputed using the last available data carried forward method due to loss to follow-up.

Recruitment took place from September 2010 to April 2011 and the intervention ran from May 2011 until May 2013. All practices and peer supporters continued to participate during the whole study period.

3.2. Process Evaluation {#sec3.2}
-----------------------

Peer supporters visited median 5 (0--6) of the six peer supporter training sessions. The median number of physical activity meetings per group was 86 (1--104) with an achievable maximum of 104 times (once per week for two years). The median number of physical activity meetings of individual patients was 23 (0--90). Physical education trainers supported the groups in 11% of all performed physical activity meetings (148 of 1344).

Peer groups met 12 (0--14) times for all educational and conversational meetings (67% of 15 possible meetings), and of these 8 (0--8) were supported by a professional. Individual patients participated in 4 (0--14) of these meetings (34% of all meetings). In total, 178 group meetings were performed by the peer groups, of which 126 (72.4%) were supported by a professional.

3.3. Baseline Data {#sec3.3}
------------------

The baseline characteristics of the participants were balanced between the study groups ([Table 2](#tab2){ref-type="table"}).

3.4. Follow-Up Results {#sec3.4}
----------------------

Using univariate analysis (independent *t*-test) or mixed models adjusting for baseline values and cluster effects, we found no significant differences between the intervention group and the control group regarding our primary and most secondary outcomes (Tables [3](#tab3){ref-type="table"} and [4](#tab4){ref-type="table"}). Quality of life decreased in the intervention group and slightly improved in the control group, with a significant difference between groups in favour of the controls (EQ-5D index and EQ-5D VAS, [Table 3](#tab3){ref-type="table"}). Only the difference in EQ-5D-VAS remains significant after adjustment for baseline value and cluster effects ([Table 4](#tab4){ref-type="table"}). There was no significant difference between the intervention and control groups regarding smoking cessation. Four of 124 patients (3.2%) in the intervention group stopped smoking compared to two of 146 (1.4%) patients in the control group (*p* = 0.649).

For safety reasons we calculated the relative risk of the intervention for death or cardiovascular events (per-protocol analysis). No significant differences between the two groups could be seen ([Table 5](#tab5){ref-type="table"}).

4. Discussion {#sec4}
=============

Our study showed that a group based peer support intervention as an additional component to a traditional disease management programme on type 2 diabetes in general practice is feasible. Although peer support appears to be a very promising approach, our intervention did not significantly improve clinical outcomes or risk profile. A slight negative effect could even be seen regarding health related quality of life.

As demonstrated by the UKPDS \[[@B22]\], HbA~1c~ levels gradually worsen over time with a rise of about 0.1% (−22.4 mmol/mol) per year. We therefore postulated an increase of HbA~1c~ of about 0.2% (−21.31 mmol/mol) in the control group and a small decrease of HbA~1c~ in the intervention group, basing our sample size calculation on a net difference of 0.5% (−18.03 mmol/mol) in HbA~1c~ change over the two years of follow-up. Our supposition was only partly fulfilled: While HbA~1c~ rose in controls it did not decrease in the intervention group but was only kept unchanged. We therefore missed to show a significant effect of our peer support intervention on our primary endpoint. A larger sample and a longer follow-up would be needed to show whether the peer support intervention can significantly prevent the rise in HbA~1c~ in the long run.

Our findings may at least partially be due to the well-controlled baseline values, leaving little room for improvement. Although general practitioners had been asked to recruit all patients with type 2 diabetes consecutively, we suspect that recruitment was performed differentially giving priority to well-controlled patients. Also, the intensity of the intervention may have been too low to demonstrate an effect on HbA~1c~. Increased professional support would have intensified the intervention, but this would have been contradictory to our intention of implementing group based peer support with a main focus on patient self-management. Due to withdrawal of consent, some groups were smaller than planned with a potentially negative impact on group dynamics.

Although quality of life was a predefined secondary outcome in our study we do not suggest to overestimate the marginally significant negative effect seen in our results. Firstly, a difference of 4 points on a VAS with 100 points does not seem clinically relevant. Secondly, this result could very well be due to chance in multiple testing. On the other hand, a decrease in quality of life as a consequence of our intervention cannot be ruled out and should be carefully considered as a possible detrimental effect of the programme. A reduction in well-being was also described in the study of Smith et al. who evaluated a peer support programme for type 2 diabetes mellitus in Ireland \[[@B23]\]. Smith postulates that peer support could cause peer supporters to focus on negative experiences which may have a negative effect on all participants. The increase of physical activity could also lead to discomfort in patients not used to exercising, thus compromising quality of life.

4.1. Comparison with Other Studies {#sec4.1}
----------------------------------

Our results are in line with the majority of peer support trials that could not demonstrate a positive effect on HbA~1c~ \[[@B23]--[@B27]\]. Only very few controlled studies could show that peer support has a significant impact on glycaemic control in patients with type 2 diabetes \[[@B16], [@B28], [@B29]\]. All of the three positive studies were of short duration (≤6 months) and tested quite specific interventions like counselling via telephone or an online programme. According to the aforementioned systematic review, studies on peer support are in general heterogeneous in terms of setting, intervention, study design, length of follow-up, and outcome measures, and often the quality is low \[[@B17]\]. We could only identify one long-term randomised controlled trial exploring the effect of a peer group based intervention. This Irish study, like our study, showed disappointing results regarding the effect of peer support on metabolic control and, as mentioned above, also detected a possible negative effect on quality of life \[[@B23]\]. Compared to our trial, the intervention examined in Smith\'s study was of very low intensity: Study participants had only nine meetings with peer supporters in two years, and peer supporters only had two evening training sessions. We hypothesized that our more intensive peer support intervention would have a more notable effect on HbA~1c~. However, our results are consistent with the Irish peer support intervention. It remains unclear how to design and implement peer support as a structured intervention to effectively optimise metabolic control.

Some peer support studies for type 2 diabetes have shown benefits for participants using other outcome measures compared to HbA~1c~ such as healthier eating habits \[[@B27], [@B30], [@B31]\], health distress \[[@B16], [@B27], [@B28]\], blood pressure \[[@B32]\], BMI \[[@B30]\], or depression \[[@B31]\]. For all of these outcomes there exist other studies which did not find any effect \[[@B17]\], and in their systematic review Dale et al. draw the conclusion that no consistent evidence exists that supports a general benefit of peer support interventions \[[@B17]\].

4.2. Strengths and Limitations {#sec4.2}
------------------------------

This cluster-randomised controlled trial is one of the largest randomised trials on group peer support, and no existing controlled study provided longer follow-up than ours. Our peer support intervention was well designed, and process evaluation assured that the intervention was largely delivered as planned. Loss to follow-up (6.8%) was low, and the amount of missing data was acceptable for a pragmatic trial. Diabetes care was well structured by the existing DMP in both the intervention and the control group, assuring that any differences in outcome could be attributed to the intervention and not to differences in standard health care delivery. All of these characteristics of our study assure a high degree of internal validity.

Nonetheless there are several sources of possible bias possibly compromising our study results. To avoid selection bias and to assure concealment of allocation, neither physicians nor patients knew at the time of signing up whether they would participate in the peer support programme or serve as controls. A number of patients dropped out after randomisation into the intervention group, presumably willing to participate in the study only as controls. Selection bias may have occurred here.

As mentioned above, differential recruitment of healthy patients by the general practitioners may have led to sampling bias or healthy user bias. There was little room for improvement of metabolic control in our study population which thwarted our power calculation. HbA~1c~ improvement by 0.5% is not a clinically realistic expectation when starting from a baseline HbA~1c~ of 7%. Our peer support intervention might therefore be more effective in patients with poor glycemic control. On the other hand, peer support is probably not suitable for all patients, and intentionally recruiting less well patients may lead to low participation rates in the group sessions, thus also compromising a possible effect.

Preselecting participants by restricting inclusion to patients enrolled in the DMP might be another source of sampling bias. In Salzburg, only about 10% of all patients with type 2 diabetes have been enrolled in the DMP at the beginning of our study. Thus external validity of our study is limited due to various reasons even though internal validity is high.

Attendance rates of the group sessions in our study were good but not excellent. Some patients only attended the discussion meetings and avoided the exercise meetings, thus compromising their chance to improve metabolic control by physical activity. Although patients and peer supporters were instructed and motivated to do additional exercising at home, most patients probably only participated in the physical activity group meetings once a week. This intervention may have been not sufficiently intense to exert an influence on our primary endpoint.

As the intervention made it necessary to preform groups of patients living close to each other, and due to the group based intervention, randomisation on the patient level was not possible. Bias due to cluster effects can be minimized by multilevel modelling but there remains a risk of cluster bias due to undetected confounders.

Our power calculation was based on a 0.5% (−18.03 mmol/mol) difference in HbA~1c~ reduction between intervention and control which was not achieved. Nonetheless HbA~1c~ increased by 0.1% (−22.4 mmol/mol) in controls, and this increase was apparently avoided by the peer support intervention. A much larger sample size and longer follow-up would be needed, though, to make this result significant.

As we know from the ACCORD study, low HbA~1c~ levels are not necessarily related to better outcome \[[@B33]\]. Therefore it might be postulated that HbA~1c~ is not a suitable outcome measurement in studies of type 2 diabetes. We agree to this postulate in intervention studies focused on drugs, but we believe that HbA~1c~ still is an acceptable outcome measure in studies focused on lifestyle changes. We evaluated clinically relevant outcomes like event rates and mortality as safety measures in our study, but follow-up certainly was not long enough to expect any significant effects of the intervention here.

4.3. Conclusions and Policy Implications {#sec4.3}
----------------------------------------

A group based peer support intervention as an additional component of a disease management programme on type 2 diabetes is feasible. It enables general practitioners to offer additional support to patients willing to be active and change their lifestyle, it requires minimal effort from the general practitioners, and it can be offered at low cost as the intervention is mainly carried out by the patients themselves. Our intervention tends to maintain HbA~1c~ while it gradually worsens in controls as has been shown in other studies like the UKPDS. Larger randomised controlled trials with a longer follow-up are needed to demonstrate the significance of this finding and to evaluate the effects of peer support on clinically relevant endpoints. To date, evidence is insufficient to give a general recommendation regarding the implementation of peer support programmes, but we believe that the concept provides an additional opportunity for chronically ill patients and therefore deserves further research.

The authors would like to thank all participating general practitioners of Salzburg and their teams, the peer support leaders, and patients for making this study possible. They also thank the scientific advisory board of the study, R. A. Gabbay, M.D., Ph.D., T. Tang, Ph.D., and P. Kowatsch, M.D., as well as the BRIDGES team, namely, R. L\'Heveder, for their continuous support. This project was supported by a BRIDGES Grant (Bringing Research in Diabetes to Global Environments and Systems) from the International Diabetes Federation (Grant no. LT09-261). BRIDGES, an International Diabetes Federation Project, is supported by an educational grant from Lilly Diabetes.

ACCORD:

:   Action to Control Cardiovascular Risk in Diabetes

BMI:

:   Body mass index

CHD:

:   Coronary heart disease

DMP:

:   Disease management programme

HbA~1c~:

:   Haemoglobin A~1c~

HDL:

:   High density lipoprotein

LDL:

:   Low density lipoprotein

UKPDS:

:   United Kingdom Prospective Diabetes Study

VAS:

:   Visual analogue scale.

Conflict of Interests
=====================

None of the authors have any additional conflict of interests.

Authors\' Contribution
======================

Tim Johansson and Sophie Keller contributed equally in writing the paper and carrying out the study. Andreas C. Sönnichsen designed the study and was principle investigator, supported by Raimund Weitgasser with diabetological expertise. Henrike Winkler and Raimund Weitgasser contributed substantially in designing and carrying out the study. Statistical analysis was performed by Thomas Ostermann, Sophie Keller, and Andreas C. Sönnichsen. All authors reviewed and approved the final paper.

Disclosure
==========

Lilly Diabetes does not have privileged access to applications or to funded projects. Any results, including data and intellectual property rights, from funded projects will become the property of the International Diabetes Federation, which will put them in the public domain to the extent permitted by applicable data protection and privacy laws. Lilly Diabetes has one representative, as an observer with no voting rights, in the Executive Committee of BRIDGES and no representative in the Review Committee. Lilly Diabetes is not informed of the composition of the Review Committee. Lilly Diabetes does not have access to the data of this study and is not involved in the evaluation of these data.

![CONSORT diagram for recruitment and follow-up of clusters and participants.](JDR2016-3248547.001){#fig1}

###### 

Topics for the group meetings and newsletters.

  Year   Month                                          Topic/newsletter                            Professional
  ------ ---------------------------------------------- ------------------------------------------- --------------
  2011   10--12                                         Healthy diet: dietary change step by step   Nutritionist
                                                                                                    
  2012   01                                             Self-motivation and group motivation        ---
  02     Lifestyle changes                              Psychologist                                
  03     Daily self-management, medical checks          ---                                         
  04     Diabetes: therapy, blood glucose measurement   General practitioner                        
  05     Sweeteners                                     ---                                         
  06     Weight loss, weight control                    Nutritionist                                
  07     Physical activity in daily routine             ---                                         
  08     Physical activity and motivational problems    Sports scientist                            
  09     Cardiovascular risk management                 General practitioner                        
  10     Prevention of diabetic complications           ---                                         
  11     Glycaemic index and glycaemic load             Nutritionist                                
  12     Prevention of weight gain at Christmas         ---                                         
                                                                                                    
  2013   01                                             Diabetes and depression                     Psychologist
  02     Diabetes and alcohol; smoking cessation        ---                                         

###### 

Baseline characteristics of participants.

  ----------------------------------------------------------------------------------
                                       *n* (I/C)^a^   Intervention \   Control \
                                                      *n* = 148        *n* = 189
  ------------------------------------ -------------- ---------------- -------------
  Age (years, SD)                      148/189        62.2 (8.8)       63.6 (10.8)

                                                                       

  Female (*n*, %)                      148/189        76 (51.4)        97 (51.3)

                                                                       

  Duration of diabetes (years, SD)     145/178        8.4 (7.1)        7.0 (5.6)

                                                                       

  Smokers (*n*, %)                     141/183        17 (12.1)        22 (12.0)

                                                                       

  Married (*n*, %)                     145/182        99 (68.3)        121 (66.5)

                                                                       

  Low level of education^b^ (*n*, %)   143/181        126 (88.1)       164 (90.6)

                                                                       

  Retired (*n*, %)                     145/183        95 (65.6)        126 (68.8)

                                                                       

  Living alone (*n*, %)                144/178        30 (20.8)        37 (20.8)
  ----------------------------------------------------------------------------------

^a^Variation of *n* due to missing values; I = intervention group, C = control group.

^b^Only grade school, apprenticeship.

###### 

Clinical outcomes at baseline and follow-up by study group.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                          Intervention   Control        Mean difference\      *p*-value^c^                                                        
                                                                        between groups^b^ \                                                                       
                                                                        (95% CI)                                                                                  
  --------------------------------------- -------------- -------------- --------------------- -------------- -------------- -------------- ---------------------- -------
  Primary endpoint                                                                                                                                                

                                                                                                                                                                  

  HbA~1c~ (%)                             143            7.02 (1.25)    7.05 (1.10)           185            7.08 (1.25)    7.21 (1.31)    0.10 (−0.14 to 0.35)   0.41

                                                                                                                                                                  

  Secondary endpoints                                                                                                                                             

                                                                                                                                                                  

  *Laboratory results (mg/dL)*                                                                                                                                    

  Creatinine                              139            0.86 (0.23)    0.90 (0.25)           162            0.96 (0.33)    1.00 (0.64)    0.01 (−0.07 to 0.10)   0.77

  Triglycerides                           139            150.8 (86.4)   147.9 (81.1)          164            151.7 (94.3)   147.2 (83.7)   −1.5 (−20.2 to 17.2)   0.88

  Cholesterol                             139            189.5 (40.1)   187.1 (40.3)          164            190.5 (44.8)   184.4 (40.6)   −3.6 (−12.8 to 5.5)    0.43

  HDL                                     139            54.9 (14.4)    57.1 (18.7)           163            54.8 (16.4)    55.0 (15.0)    −2.0 (−4.9 to 0.9)     0.17

  LDL                                     136            106.3 (35.9)   100.3 (37.0)          161            106.7 (38.9)   99.1 (35.7)    −1.1 (−9.3 to 7.1)     0.79

                                                                                                                                                                  

  *Anthropometric measurements*                                                                                                                                   

  BMI (kg/m^2^)                           133            31.0 (5.3)     30.7 (5.3)            159            30.3 (4.8)     29.9 (4.9)     −0.1 (−0.6 to 0.3)     0.65

  Systolic blood pressure (mmHg)          128            136.0 (15.7)   136.0 (15.7)          154            137.2 (17.9)   136.3 (15.8)   −1.0 (−5.2 to 3.2)     0.65

  Diastolic blood pressure (mmHg)         128            80.8 (9.1)     80.4 (8.5)            154            80.4 (10.0)    80.8 (8.6)     0.8 (−1.7 to 3.2)      0.52

                                                                                                                                                                  

  *UKPDS-Risk Engine: 10-year risk* ^f^                                                                                                                           

  CHD^d^                                  76             15.0 (9.3)     16.9 (11.0)           85             15.3 (9.9)     17.1 (9.6)     0.0 (−1.9 to 1.9)      0.99

  Fatal CHD                               76             10.2 (7.5)     12.2 (9.3)            85             10.2 (8.6)     12.1 (8.4)     −0.1 (−1.6 to 1.3)     0.85

  Stroke                                  76             8.9 (7.3)      11.3 (9.4)            85             9.1 (8.4)      11.2 (9.2)     −0.4 (−1.2 to 0.3)     0.27

  Fatal stroke                            76             1.3 (1.3)      1.8 (1.8)             85             1.4 (1.5)      1.6 (1.4)      −0.2 (−0.5 to −0.0)    0.047

                                                                                                                                                                  

  *Quality of life (EQ-5D)*                                                                                                                                       

  Index                                   128            0.90 (0.16)    0.87 (0.20)           149            0.88 (0.19)    0.88 (0.19)    0.04 (−0.0 to 0.1)     0.051

  VAS^e^                                  117            75.1 (17.0)    72.8 (20.0)           130            70.9 (17.4)    73.7 (18.8)    5.2 (0.6 to 9.8)       0.03
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^Variation of *n* due to missing values; BL = baseline; FU = follow-up.

^b^Mean difference between groups is calculated by subtracting mean pre-post-difference of the control group from mean pre-post-difference of the intervention group.

^d^Independent *t*-test, unadjusted.

^4^CHD = coronary heart disease.

^e^VAS = visual analogue scale.

^f^The reduced *n* is due to the fact that the UKPDS-risk engine can only be applied to patients in primary prevention.

###### 

Differences between groups regarding primary and secondary outcome measures, adjusted for baseline values, age, and ICC.

                                          *n* (I/C)   Mean difference between groups^b^   ICC^a^   *p* value
  --------------------------------------- ----------- ----------------------------------- -------- -----------
  Primary endpoint                                                                                 
                                                                                                   
  HbA~1c~ (%)                             143/185     0.14 (−0.08 to 0.36)                −0.05    0.22
                                                                                                   
  Secondary endpoints                                                                              
                                                                                                   
  *Laboratory results (mg/dL)*                                                                     
  Creatinine (mg/dL)                      139/162     0.00 (−0.09 to 0.08)                −0.01    0.92
  Triglycerides (mg/dL)                   139/164     0.17 (−15.54 to 15.88)              0.00     0.98
  Total cholesterol (mg/dL)               139/164     −2.28 (−10.05 to 5.48)              0.05     0.56
  HDL cholesterol (mg/dL)                 139/163     −1.94 (−4.69 to 0.81)               0.17     0.17
  LDL cholesterol (mg/dL)                 136/161     −0.37 (−7.48 to 6.74)               0.06     0.91
                                                                                                   
  *Anthropometric measurements*                                                                    
  BMI (kg/m^2^)                           133/159     −0.15 (−0.58 to 0.29)               −0.03    0.51
  Systolic blood pressure (mmHg)          128/154     −0.56 (−3.96 to 2.84)               −0.05    0.75
  Diastolic blood pressure (mmHg)         128/154     0.51 (−1.39 to 2.41)                −0.02    0.60
                                                                                                   
  *UKPDS-Risk Engine: 10-year risk* ^e^                                                            
  CHD^c^                                  76/85       0.10 (−1.75 to 1.95)                0.03     0.92
  Fatal CHD                               76/85       −0.09 (−1.53 to 1.36)               0.03     0.91
  Stroke                                  76/85       −0.43 (−1.07 to 0.22)               −0.03    0.20
  Fatal stroke                            76/85       −0.22 (−0.44 to 0.00)               −0.07    0.053
                                                                                                   
  *Quality of life (EQ-5D)*                                                                        
  Index                                   128/149     0.04 (−0.00 to 0.08)                −0.01    0.08
  VAS^d^                                  117/130     4.30 (0.08 to 8.53)                 0.01     0.046

^a^ICC = intracluster correlation coefficient.

^b^Δ adjusted = adjusted mean difference, calculated using mixed models. Mean difference is calculated by subtracting mean pre-post-difference of the control group from mean pre-post-difference of the intervention group. Positive values indicate higher reductions in the intervention group compared to controls. Negative values indicate an increase in the intervention group compared to controls.

^c^CHD = coronary heart disease.

^d^VAS = visual analogue scale.

^e^The reduced *n* is due to the fact that the UKPDS-risk engine can only be applied to patients in primary prevention.

###### 

Cardiovascular events and mortality.

  ------------------------------------------------------------------------------------------------
  Event                               Intervention \   Control \   Relative risk   95% CI
                                      *n* = 139        *n* = 166                   
  ----------------------------------- ---------------- ----------- --------------- ---------------
  Death                               5                4           1.49            0.41 to 5.45

  Myocardial infarction               2                4           0.60            0.11 to 3.21

  Bypass or stenting                  8                6           1.59            0.57 to 4.48

  Stroke                              2                1           2.39            0.22 to 26.06

  Any cardiovascular event            9                8           1.34            0.53 to 3.39

  Any cardiovascular event or death   13               12          1.29            0.61 to 2.74
  ------------------------------------------------------------------------------------------------

[^1]: Academic Editor: Rodica Pop-Busui
